Shared on 03 Sep 25
Fair value Increased 2.70%Branded Portfolio Expansion Will Drive Global Emerging Market Access
The modest upward revision in Glenmark Pharmaceuticals' consensus price target to ₹2246 appears primarily driven by a slightly higher future P/E multiple, with revenue growth forecasts largely unchanged. What's in the News Glenmark announced the upcoming US launch of Micafungin for Injection, entering a $60.7 million annual market with a bioequivalent product to Astellas Pharma's Mycamine.
Shared on 24 Jul 25
Fair value Increased 6.13%Branded Portfolio Expansion Will Drive Global Emerging Market Access
With Glenmark Pharmaceuticals' future P/E ratio edging up from 31.26x to 32.17x while net profit margin remains stable, the consensus analyst price target is unchanged at ₹2061. What's in the News Glenmark launched TEVIMBRA® (tislelizumab), an anti-PD-1 monoclonal antibody for NSCLC and ESCC, marking its entry into immune-oncology in India.
Shared on 01 May 25
Fair value Increased 31%Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
Shared on 23 Apr 25
Fair value Increased 0.30%Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Decreased 0.091%Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 0.75%Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 6.13%Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 0.98%Upcoming Diabetes And Respiratory Launches To Expand Product Portfolio
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 1.74%